Highly accurate step counting at variouswalking states using low-cost inertial measurement unit support indoor positioning system

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. Accurate step counting is essential for indoor positioning, health monitoring systems, and other indoor positioning services. There are several publications and commercial applications in step counting. Nevertheless, over-counting, under-counting, and false walking problems are still encountered in these methods. In this paper, we propose to develop a highly accurate step counting method to solve these limitations by proposing four features: Minimal peak distance, minimal peak prominence, dynamic thresholding, and vibration elimination, and these features are adaptive with the user’s states. Our proposed features are combined with periodicity and similarity features to solve false walking problem. The proposed method shows a significant improvement of 99.42% and 96.47% of the average of accuracy in free walking and false walking problems, respectively, on our datasets. Furthermore, our proposed method also achieves the average accuracy of 97.04% on public datasets and better accuracy in comparison with three commercial step counting applications: Pedometer and Weight Loss Coach installed on Lenovo P780, Health apps in iPhone 5s (iOS 10.3.3), and S-health in Samsung Galaxy S5 (Android 6.01)

Antimonotonicity, Crisis and Multiple Attractors in a Simple Memristive Circuit

Peer reviewedPostprin

An exceptionally potent inhibitor of human CD73

The research described in this manuscript was fully funded by Arcus Biosciences, Inc. a publicly traded biotechnology company.We recently reported the initiation of a Phase I clinical trial with AB680, a potent human CD73 inhibitor, being developed for the treatment of solid tumors (NCT03677973). We undertook a detailed kinetic analysis of the interaction between human CD73 and AB680 to determine the mode of inhibition. We found AB680 to be a reversible, slow-onset competitive inhibitor of human CD73 with a Ki of 5 pM. Clinical candidates of this potency are uncommon and deserve special consideration during lead optimization.PostprintPeer reviewe

Brief Report: A Phase IIb Trial of a Novel Extended‐Release Microsphere Formulation of Triamcinolone Acetonide for Intraarticular Injection in Knee Osteoarthritis

Objective: FX006 is a novel, microsphere‐based, extended‐release formulation of triamcinolone acetonide for intraarticular (IA) injection designed to maintain treatment concentration in the joint and provide prolonged analgesic benefits in patients with osteoarthritis (OA) of the knee. This study was undertaken to compare the analgesic benefits of 2 FX006 doses with saline placebo injection. Methods: In this phase IIb study, participants with knee OA (Kellgren/Lawrence grade 2–3) and average daily pain (ADP) intensity ≥5 to ≤9 (on a 0–10 Numerical Rating Scale) were randomized (1:1:1) to receive single IA injections of FX006 32 mg (n = 104) or 16 mg (n = 102) or saline placebo (n = 100). The primary end point was the least squares mean (LSM) change from baseline to week 12 in weekly mean ADP intensity scores for FX006 32 mg versus saline placebo. Results: The primary end point was not met (LSM change at week 12 −3.1 with FX006 32 mg versus −2.5 with saline placebo; LSM difference [95% confidence interval] −0.58 [−1.22, 0.07]) (P = 0.08). However, improvements in ADP intensity were significantly greater with FX006 32 mg than saline placebo at weeks 1–11 and week 13. Improvements in ADP intensity were significantly greater with FX006 16 mg versus saline placebo at weeks 1–9. A dose‐response effect in duration of maximal analgesic effect was evident (13 weeks with 32 mg versus 9 weeks with 16 mg), with FX006 32 mg providing increased therapeutic benefit relative to FX006 16 mg. All treatments were well tolerated. Conclusion: Although the primary end point was not met, our findings indicate a prolonged reduction in symptoms with FX006 with an evident dose response and a safety profile similar to saline placebo

Formulation Mixte Vitesse-Déplacement pour Viscoélasticité - Confrontation Expérimentale et Numérique

National audienceL'objectif de ce travail est de modéliser le comportement des matériaux polymère injectés sous sollicitations dynamiques par une approche monolithique. Basé sur les équations de Navier-Stokes, nous proposons une méthode des éléments finis mixtes avec une interpolation P1+/P1 utilisant le déplacement (ou la vitesse) et la pression en tant que principales variables. La technique implémentée utilise un maillage composé de triangles (2D) ou de tétraèdres (3D) [6]. Le but de cette approche est de modéliser le comportement viscoélastique des matériaux polymère où les milieux visqueux et élastiques sont mélangés en utilisant une approche multiphasique en vitesse et déplacement. L'idée de base est d'utiliser une formulation mixte (u, v, p) avec un modèle de fermeture F(du / dt,v) = 0 , où les deux champs u et v représentent les principales variables de la déformation et de la vitesse de déformation.See http://hal.archives-ouvertes.fr/docs/00/59/26/75/ANNEX/r_ABQP7S30.pd

Chemotherapy in Cutaneous Melanoma: Is There Still a Role?

Purpose of review: In the preceding decade, the management of metastatic cutaneous melanoma has been revolutionised with the development of highly effective therapies including immune checkpoint inhibitors (specifically CTLA-4 and PD-1 inhibitors) and targeted therapies (BRAF and MEK inhibitors). The role of chemotherapy in the contemporary management of melanoma is undefined. Recent findings: Extended analyses highlight substantially improved 5-year survival rates of approximately 50% in patients with metastatic melanoma treated with first-line therapies. However, most patients will progress on these first-line treatments. Sequencing of chemotherapy following failure of targeted and immunotherapies is associated with low objective response rates and short progression-free survival, and thus, meaningful benefits to patients are minimal. Chemotherapy has limited utility in the contemporary management of cutaneous melanoma (with a few exceptions, discussed herein) and should not be the standard treatment sequence following failure of first-line therapies. Instead, enrolment onto clinical trials should be standard-of-care in these patients. Summary: Chemotherapy has limited utility in the contemporary management of cutaneous melanoma (with a few exceptions, discussed herein) and should not be the standard treatment sequence following failure of first-line therapies. Instead, enrolment onto clinical trials should be standard-of-care in these patients

Blockchain for the metaverse: A Review

Since Facebook officially changed its name to Meta in Oct. 2021, the metaverse has become a new norm of social networks and three-dimensional (3D) virtual worlds. The metaverse aims to bring 3D immersive and personalized experiences to users by leveraging many pertinent technologies. Despite great attention and benefits, a natural question in the metaverse is how to secure its users’ digital content and data. In this regard, blockchain is a promising solution owing to its distinct features of decentralization, immutability, and transparency. To better understand the role of blockchain in the metaverse, we aim to provide an extensive survey on the applications of blockchain for the metaverse. We first present a preliminary to blockchain and the metaverse and highlight the motivations behind the use of blockchain for the metaverse. Next, we extensively discuss blockchain-based methods for the metaverse from technical perspectives, such as data acquisition, data storage, data sharing, data interoperability, and data privacy preservation. For each perspective, we first discuss the technical challenges of the metaverse and then highlight how blockchain can help. Moreover, we investigate the impact of blockchain on key-enabling technologies in the metaverse, including Internet-of-Things, digital twins, multi-sensory and immersive applications, artificial intelligence, and big data. We also present some major projects to showcase the role of blockchain in metaverse applications and services. Finally, we present some promising directions to drive further research innovations and developments toward the use of blockchain in the metaverse in the future

Urinary peptides as a novel source of T Cell allergen epitopes

Mouse allergy in both laboratory workers and in inner-city children is associated with allergic rhinitis and asthma, posing a serious public health concern. Urine is a major source of mouse allergens, as mice spray urine onto their surroundings, where the proteins dry up and become airborne on dust particles. Here, we tested whether oligopeptides that are abundant in mouse urine may contribute to mouse allergic T cell response. Over 1,300 distinct oligopeptides were detected by mass spectrometry analysis of the low molecular weight filtrate fraction of mouse urine (LoMo). Posttranslationally modified peptides were common, accounting for almost half of total peptides. A pool consisting of 225 unique oligopeptides of 13 residues or more in size identified within was tested for its capacity to elicit T cell reactivity in mouse allergic donors. Following 14-day in vitro stimulation of PBMCs, we detected responses in about 95% of donors tested, directed against 116 distinct peptides, predominantly associated with Th2 cytokines (IL-5). Peptides from non-urine related proteins such as epidermal growth factor, collagen, and Beta-globin accounted for the highest response (15.9, 9.1, and 8.1% of the total response, respectively). Peptides derived from major urinary proteins (MUPs), kidney androgen-regulated protein (KAP), and uromodulin were the main T cell targets from kidney or urine related sources. Further ex vivo analysis of enrichment of 4-1BB expressing cells demonstrated that LoMo pool-specific T cell reactivity can be detected directly ex vivo in mouse allergic but not in non-allergic donors. Further cytometric analysis of responding cells revealed a bone fide memory T cell phenotype and confirmed their Th2 polarization. Overall, these data suggest that mouse urine-derived oligopeptides are a novel target for mouse allergy-associated T cell responses, which may contribute to immunopathological mechanisms in mouse allergy